Davenport & Co’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Davenport & Co’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$396K	Buy	+4,071	New	+$382K	﹤0.01%	1091

Other funds holding PBE

YHB Investment Advisors West Hartford, Connecticut $1.59B AUM 21.04% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Independent Financial Group San Diego, California $5.51B AUM 33.52% 1-Year Est. Return

Dynamic Advisor Solutions Phoenix, Arizona $3.52B AUM 15.33% 1-Year Est. Return

MinichMacGregor Wealth Management Saratoga Springs, New York $620M AUM 32.35% 1-Year Est. Return

Allen Mooney & Barnes Investment Advisors Thomasville, Georgia $673M AUM 20.03% 1-Year Est. Return

First PREMIER Bank Sioux Falls, South Dakota $621M AUM 13.03% 1-Year Est. Return

Harbor Investment Advisory Lutherville, Maryland $1.47B AUM 24.2% 1-Year Est. Return

Realta Investment Advisors Wilmington, Delaware $342M AUM 30.02% 1-Year Est. Return

Davenport & Co's PBE Position: Q3 2026 in Review

Davenport & Co opened a new position in Invesco Biotechnology & Genome ETF (PBE) in Q3 2026: 4,071 shares worth $396K. The stake represents ﹤0.01% of the portfolio and ranks #1091 among its holdings.

12 funds tracked by Wall St. Rank hold PBE as of Q3 2026.

Davenport & Co held 4,071 shares of Invesco Biotechnology & Genome ETF worth $396K as of Q3 2026.
Invesco Biotechnology & Genome ETF was a new Davenport & Co position in Q3 2026.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Davenport & Co's portfolio in Q3 2026, its #1091 holding.
12 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.

Based on Davenport & Co's 13F filing for Q3 2026, filed 14 Oct 2026.